Sight Sciences Q4 2024 Earnings Report $2.29 -0.11 (-4.58%) As of 04:00 PM Eastern Earnings HistoryForecast Sight Sciences EPS ResultsActual EPS-$0.23Consensus EPS -$0.22Beat/MissMissed by -$0.01One Year Ago EPS-$0.22Sight Sciences Revenue ResultsActual Revenue$19.07 millionExpected Revenue$18.98 millionBeat/MissBeat by +$99.00 thousandYoY Revenue GrowthN/ASight Sciences Announcement DetailsQuarterQ4 2024Date3/5/2025TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseSGHT Earnings HistorySlide DeckFull Screen Slide DeckPowered by Remove Ads Sight Sciences Earnings HeadlinesSight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8thMarch 25, 2025 | globenewswire.comSight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 GuidanceMarch 7, 2025 | nasdaq.comTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public. April 1, 2025 | Paradigm Press (Ad)Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | msn.comSight Sciences price target lowered to $3.50 from $5.50 at Piper SandlerMarch 6, 2025 | markets.businessinsider.comSight Sciences (SGHT) Receives a Hold from Piper SandlerMarch 6, 2025 | markets.businessinsider.comSee More Sight Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sight Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sight Sciences and other key companies, straight to your email. Email Address About Sight SciencesSight Sciences (NASDAQ:SGHT), an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.View Sight Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
